Novelix Pharmaceuticals Limited has scheduled an Extra Ordinary General Meeting (EGM) on July 1, 2026, to seek shareholder approval for the preferential allotment of 12,00,000 equity shares to non-promoters, aiming to raise ₹6.84 crore. The issuance, priced at ₹57 per share including a premium of ₹47, is intended to bolster financial resources for specific growth initiatives including lab-scale technology transfer, land development, and the acquisition of quality control equipment. The board approved the proposal at a meeting held on June 4, 2026, and the company has fixed June 24, 2026, as the record date to determine shareholder eligibility for the meeting.

The proposed allotment targets 18 specific investors identified as public shareholders and complies with Section 42 and 62 of the Companies Act, 2013, along with the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Venkateshwarlu Pulluru, Whole-time Director, signed the regulatory filing submitted to the exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The special resolution authorizes the board to complete the allotment within 15 days of the meeting, subject to necessary regulatory approvals.

Preferential Allotment Details

The breakdown of the proposed issuance to non-promoters is detailed below:

Utilization of Proceeds

The company plans to deploy the funds towards specific operational and developmental needs. The estimated utilization is as follows:

EGM and Voting Schedule

The EGM is scheduled for July 1, 2026, at 3:30 PM via video conferencing. Remote e-voting facilities will be available to eligible shareholders from June 28 at 9:00 am to June 30 at 5:00 pm. The voting rights shall be reckoned based on the paid-up value of shares held as on the cut-off date of June 24, 2026. The company has appointed Mr. Bharat Khaniwal, Practicing Company Secretary, as the scrutinizer for the e-voting process.

trimurthi has entered into an agreement with GMBU e.V., Halle (Saale), Germany, to facilitate the commercial scale-up of Astaxanthin production. This strategic move aims to transition the product from pilot scale to full commercial manufacturing at the company's research facilities in Hyderabad, India. The development is significant as it marks the progression of Novelix Pharmaceuticals Limited's capabilities in producing high-value nutraceutical ingredients.

The agreement was executed on June 2, 2026, under Regulation 30 of the listing regulations. Disclosures confirm that no special rights, such as the right to appoint directors or preferential share subscription, have been agreed upon between the parties. Furthermore, the transaction does not involve any shareholding in the counterparty entity and is not classified as a related party transaction.

The filing confirms that GMBU e.V. is not related to the promoter or promoter group of Novelix Pharmaceuticals Limited. The agreement was disclosed in compliance with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026. The company's registered office is located at H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Himayat Nagar, Hyderabad, Telangana- 500029.

Key Agreement Details